We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

89 hedge funds and large institutions have $255M invested in BioSpecifics Technologies Corp. in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more capital invested

Capital invested by funds: $223M → $255M (+$31.4M)

3% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 36

7% less funds holding

Funds holding: 9689 (-7)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
89
Holders Change
-7
Holders Change %
-7.29%
% of All Funds
2.22%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
6
Increased
35
Reduced
36
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
JAM
1
JW Asset Management
Florida
$40.4M
BlackRock
2
BlackRock
New York
$20.7M +$20M +377,759 +95,153%
Renaissance Technologies
3
Renaissance Technologies
New York
$19.3M +$1.05M +19,881 +6%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$13.5M +$941K +17,774 +8%
Vanguard Group
5
Vanguard Group
Pennsylvania
$10.8M +$99.5K +1,879 +1%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$10.1M -$345K -6,523 -3%
EAM
7
Eagle Asset Management
Florida
$9.93M -$237K -4,485 -2%
ECP
8
Elk Creek Partners
Colorado
$8.28M +$265K +5,011 +3%
NI
9
Numeric Investors
Massachusetts
$8.12M -$315K -5,954 -4%
RHJA
10
Rice Hall James & Associates
California
$7.15M -$80.4K -1,519 -1%
NC
11
Northpointe Capital
Michigan
$6.75M -$218K -4,125 -3%
State Street
12
State Street
Massachusetts
$4.88M +$370K +6,998 +9%
Northern Trust
13
Northern Trust
Illinois
$4.39M -$50.2K -949 -1%
AQR Capital Management
14
AQR Capital Management
Connecticut
$4.06M +$1.03M +19,437 +36%
Wells Fargo
15
Wells Fargo
California
$3.95M -$917K -17,314 -19%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$3.95M
Bank of New York Mellon
17
Bank of New York Mellon
New York
$3.69M +$159 +3 +0%
Allianz Asset Management
18
Allianz Asset Management
Germany
$3.65M +$406K +7,676 +13%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.62M +$501K +9,462 +17%
Prudential Financial
20
Prudential Financial
New Jersey
$3.58M -$30.2K -570 -0.9%
MCM
21
Matarin Capital Management
New York
$3.25M +$626K +11,817 +25%
Goldman Sachs
22
Goldman Sachs
New York
$3.19M +$227K +4,297 +8%
Invesco
23
Invesco
Georgia
$3.04M -$94.3K -1,781 -3%
MOACM
24
Mutual of America Capital Management
New York
$3M -$68.8K -1,300 -2%
OAM
25
Oxford Asset Management
United Kingdom
$2.32M -$203K -3,831 -8%

BSTC Hedge Fund Activity: Q1 2017 in Review

89 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2017, worth a combined $255M — up 14% from $223M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BSTC and 6 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 35 added.

The largest buyer was BlackRock, adding an estimated $20M. The largest seller was RK Capital Management (Colorado), exiting entirely with an estimated $3.94M sold.

  • 89 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2017, down from 96 in Q4 2016.
  • Funds reported $255M of BioSpecifics Technologies Corp. stock for Q1 2017, up 14% quarter-over-quarter.
  • 6 funds opened new BioSpecifics Technologies Corp. positions in Q1 2017 and 8 closed out, a net change of -2 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q1 2017 was BlackRock, an estimated $20M added.
  • The largest BioSpecifics Technologies Corp. seller in Q1 2017 was RK Capital Management (Colorado), an estimated $3.94M sold.

Based on aggregated 13F filings for Q1 2017.